Literature DB >> 12480064

Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban.

David J Schneider1, Howard C Herrmann, Nasser Lakkis, Frank Aguirre, Ying Wan, Atul Aggarwal, Samer S Kabbani, Peter M DiBattiste.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12480064     DOI： 10.1016/s0002-9149(02)02892-8

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN： 0002-9149            Impact factor:   2.778


× No keyword cloud information.
  11 in total

1.  Inhibition of platelet function by abciximab or high-dose tirofiban in patients with STEMI undergoing primary PCI: a randomised trial.

Authors:  J W van Werkum; W B M Gerritsen; J C Kelder; C M Hackeng; S M Ernst; V H M Deneer; M J Suttorp; B J W M Rensing; H W M Plokker; J M Ten Berg
Journal:  Neth Heart J       Date:  2007       Impact factor: 2.380

2.  Does glycoprotein IIB/IIIA resistance exist?

Authors:  J J J Smit; A W J van 't Hof
Journal:  Neth Heart J       Date:  2007       Impact factor: 2.380

3.  Tirofiban versus abciximab: tirofiban is administered at suboptimal dosages when evaluated in an arterial thrombosis model in non-human primates.

Authors:  Walter J Janse van Rensburg; Jan P Roodt; Seb Lamprecht; S Muriel Meiring; Philip N Badenhorst
Journal:  Clin Exp Med       Date:  2012-01-05       Impact factor: 3.984

Review 4.  Anti-platelet therapy: glycoprotein IIb-IIIa antagonists.

Authors:  David J Schneider
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

5.  Different effects of tirofiban and aspirin plus clopidogrel on myocardial no-reflow in a mini-swine model of acute myocardial infarction and reperfusion.

Authors:  Y-J Yang; J-L Zhao; S-J You; Y-J Wu; Z-C Jing; W-X Yang; L Meng; Y-W Wang; R-L Gao
Journal:  Heart       Date:  2005-12-30       Impact factor: 5.994

6.  Would tirofiban have been shown non-inferior to abciximab had the TENACITY trial not been terminated for financial reasons?

Authors:  Peter B Berger; Judson B Williams; Vic Hasselblad; Karen Chiswell; Karen S Pieper; Robert M Califf
Journal:  J Interv Cardiol       Date:  2013-02-05       Impact factor: 2.279

Review 7.  Defining the role of platelet glycoprotein receptor inhibitors in STEMI: focus on tirofiban.

Authors:  Arnoud W J van 't Hof; Marco Valgimigli
Journal:  Drugs       Date:  2009       Impact factor: 9.546

8.  The effects of tirofiban infusion on clinical and angiographic outcomes of patients with STEMI undergoing primary PCI.

Authors:  Cihangir Kaymaz; Nurşen Keleş; Nihal Özdemir; İbrahim Halil Tanboğa; Hacer C Demircan; Mehmet M Can; Fatih Koca; İbrahim Akın İzgi; Alper Özkan; Muhsin Türkmen; Cevat Kırma; Ali M Esen
Journal:  Anatol J Cardiol       Date:  2014-12-25       Impact factor: 1.596

9.  Abciximab: a reappraisal of its use in coronary care.

Authors:  Marco Valgimigli; Gianluca Campo; Matteo Tebaldi; Roberto Carletti; Chiara Arcozzi; Roberto Ferrari; Gianfranco Percoco
Journal:  Biologics       Date:  2008-03

Review 10.  Early glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an individual patient data meta-analysis.

Authors:  G De Luca; C M Gibson; F Bellandi; S Murphy; M Maioli; M Noc; U Zeymer; D Dudek; H-R Arntz; S Zorman; H M Gabriel; A Emre; D Cutlip; G Biondi-Zoccai; T Rakowski; M Gyongyosi; P Marino; K Huber; A W J van't Hof
Journal:  Heart       Date:  2008-05-12       Impact factor: 5.994
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.